Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change.
about
Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.The role of second transplants for leukemia.Same sibling marrow following cord allogeneic transplantation as therapy for second relapse acute promyelocytic leukemia in a pediatric patient.Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant.Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.Relapse assessment following allogeneic SCT in patients with MDS and AML.Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation.Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes.Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years.Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT.Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa.Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT.Magnetic resonance enterography for assessment of intestinal graft-versus-host disease after allogeneic stem cell transplantation.Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European SocietOutcomes following second allogeneic haematopoietic transplants using fludarabine-melphalan conditioning.Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.Outcome and prognostic factors among patients who underwent a second transplantation for disease relapse post the first allogeneic cell transplantation.Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation.Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party.
P2860
Q34749088-FB5091D3-59DE-42FE-A470-14AB1355EFC4Q36204850-43E846F5-CF21-4858-9C40-5FDD8033E8C5Q36729327-BCD382FB-686C-414D-B3FD-29AE18D354ACQ37216476-B76CEB8B-1EF8-43A9-B68F-466891E9F05EQ37258220-191ABB3B-0B80-4619-92BF-0D51AD5FB9C9Q38197075-295643A7-8C6D-4F47-8A20-E1143B2B8693Q38199623-EC00113E-5E4E-4B5D-A0A0-07FF2919D396Q38219579-0AF28741-D0F9-4751-A02D-A0A935E16614Q38654516-0AA6B41B-6568-4B2D-9814-D07BE737065FQ39329093-E9F6E42D-BEBC-4F0A-9E8B-664206A90E37Q40313702-57AEDBD4-6568-4DA2-A9D5-FA26AB46C4D0Q40466623-C7B6CB83-8569-4351-8C46-D180031C1654Q40519376-627C8BFF-67BF-4E16-9AC5-3243472DB690Q40542266-E53E4432-209A-40D6-AEC9-9D7E6A394F07Q40752008-4BDCA60C-E84E-41DE-8B9D-4B239AB1D6B3Q41564670-BD19366D-D22F-4671-B72B-8663289E26BEQ41652393-353816F8-9DFF-4AFE-9C6C-A34DA1126A15Q47661085-D73FA04C-72C3-4482-9E77-E82CAD018F5CQ48329297-63EE217D-1FB0-4B5E-9B08-CD500548D440Q49905502-2745C51B-F671-4C69-B0C7-383E99434025Q50227222-E7D628FE-F059-48B3-A158-DA0C52F82BBBQ51735777-858FCA72-E70E-4A42-828C-78F868C91329Q52960823-D431BB6E-A2CB-4064-A98C-308F6230E439
P2860
Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Second allograft for hematolog ...... ors: the role of donor change.
@ast
Second allograft for hematolog ...... ors: the role of donor change.
@en
type
label
Second allograft for hematolog ...... ors: the role of donor change.
@ast
Second allograft for hematolog ...... ors: the role of donor change.
@en
prefLabel
Second allograft for hematolog ...... ors: the role of donor change.
@ast
Second allograft for hematolog ...... ors: the role of donor change.
@en
P2093
P356
P1476
Second allograft for hematolog ...... ors: the role of donor change.
@en
P2093
Christof Scheid
Christoph Schmid
Dietger Niederwieser
Dietrich Wilhelm Beelen
Donald Bunjes
Hans Martin
Hans-Jochem Kolb
Hartmut Bertz
Hubert Schrezenmeier
Johanna Tischer
P304
P356
10.1200/JCO.2012.44.7961
P407
P577
2013-08-05T00:00:00Z